Evidence map›Paper›PMID 36973504›Full record

ArticleScientific reports2023

Effect of sclerostin inactivation in a mouse model of severe dominant osteogenesis imperfecta.

Juliana Marulanda, Josephine T Tauer, Iris Boraschi-Diaz, Ghalib Bardai, Frank Rauch

Open access · goldFull text read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Juliana MarulandaShriners Hospital for Children, 1003 Decarie, Montreal, QC, H4A 0A9, Canada.
Josephine T TauerShriners Hospital for Children, 1003 Decarie, Montreal, QC, H4A 0A9, Canada.
Iris Boraschi-DiazDepartment of Pediatrics, McGill University, Montreal, QC, Canada.
Ghalib BardaiShriners Hospital for Children, 1003 Decarie, Montreal, QC, H4A 0A9, Canada.
Frank RauchShriners Hospital for Children, 1003 Decarie, Montreal, QC, H4A 0A9, Canada. frank.rauch@mcgill.ca.
McGill University · CAShriners Hospitals for Children - Canada · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteogenesis imperfecta (OI) is a rare bone disease that is associated with fractures and low bone mass. Sclerostin inhibition is being evaluated as a potential approach to increase bone mass in OI. We had previously found that in Col1a1

Indexed as

Adaptor Proteins, Signal TransducingOsteogenesis ImperfectaAnimalsBone and BonesBone DensityCancellous BoneDisease Models, AnimalMiceMice, KnockoutAdaptor Proteins, Signal TransducingSost protein, mouse

Identifiers

PMID36973504
PMCPMC10043013
OpenAlexW4360997856

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read18
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.